Uncapping conflict of interest?

Science

Volumn 340, Issue 6137, 2013, Pages 1172-1173

  Wood, Susan F ^a   Mador, Jillian K ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG; EXPERT SYSTEM; FINANCIAL SYSTEM; FOOD SAFETY; HEALTH CARE; HEALTH POLICY; ORGANIZATIONAL FRAMEWORK; POLICY REFORM; PUBLIC HEALTH; REGULATORY FRAMEWORK;

ADVISORY COMMITTEE; BIOMEDICINE; CONFLICT OF INTEREST; DECISION MAKING; FINANCE; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HEALTH CARE QUALITY; HUMAN; MEDICAL RESEARCH; MEDICAL SOCIETY; ORGANIZATION; PRIORITY JOURNAL; PUBLICATION; REVIEW; ARTICLE; ETHICS; EXPERT WITNESS; INTERPERSONAL COMMUNICATION; PRACTICE GUIDELINE; PUBLIC HEALTH; SCIENCE; STANDARD; UNITED STATES;

UNITED STATES;

CONFLICT OF INTEREST; DISCLOSURE; EXPERT TESTIMONY; GUIDELINES AS TOPIC; HUMANS; PUBLIC HEALTH; SCIENCE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

MLCS; MLOWN;

EID: 84878760983     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1231955     Document Type: Review

References (25)

1. FDA, Guidance for the Public, FDA Advisory Committee Members, and FDA Staff: Public Availability of Advisory Committee Members' Financial Interest Information and Waivers, Final Guidance (FDA, Silver Spring, MD, 2012).
2. Food and Drug Administration Safety and Innovation Act of 2012, PL 112-144, (2012).
3. Science Board to the FDA, FDA Science and Mission at Risk (FDA, Silver Spring, MD, 2007).
4. D. M. Zuckerman, FDA Advisory Committees: Does Approval Mean Safety? (National Research Center for Women and Families, Washington, DC, 2006).
5. FDA, Percent of FDA advisory committee members participating in meetings in the month who were granted waivers. Data available online through the FDA, details available in the SM.
6. S. F. Wood, K. L. Perosino, Public Health Rep. 43, 409 (2008).
7. P. B. Fontanarosa et al., JAMA 304, 1496 (2010).
8. Science, Science/AAAS Authorship Form and Statement of Conflicts of Interest (AAAS, Washington, DC, 20013).
9. European Medicines Agency, "European Expert List"; www.ema.europa.eu/ema/index.jsp?curl=pages/about-us/landing/experts.jsp&mid= WC0b01ac058043244a.
10. P. Lurie et al., JAMA 295, 1921 (2006).
11. N. Ackerley et al., Financial Conflict-of-Interest Disclosure and Voting Patterns at FDA Advisory Committee Meetings (Eastern Research Group, Arlington, VA, 2009).
12. N. Ackerley et al., Measuring Conflict of Interest and Expertise on FDA Advisory Committees (Eastern Research Group, Lexington, MA, 2007); www.fda.gov/oc/advisory/ergcoireport.pdf.
13. Health Subcommittee Hearing on Reauthorization of the Prescription Drug User Fee Act, Hearing before the Subcommittee on Health of the House Committee on Energy and Commerce, 112th Congress (1 February 2012).
14. B. Lo, M. J. Field, Eds., Conflict of Interest in Medical Research, Education and Practice (National Academy Press, Washington, DC, 2009).
15. J. Lenzer, K. Epstein, "The Yaz men: Members of FDA panel reviewing the risks of popular Bayer contraceptive had industry ties." Wash. Mon. 9 January 2012.
16. Center for Science in the Public Interest, Conflict of Interest on COX-2 Panel (Center for Science in the Public Interest, Washington, DC, 2005); www.cspinet.org/new/200502251.html.
17. G. Harris, A. Berenson, New York Times, 25 February 2005.
18. CDER, 2011 Novel New Drugs (FDA, Silver Spring, MD, 2012); www.fda.gov/downloads/Drugs/.../ucm293663.pdf.
19. FDA, Annual report on the FDA: AC vacancies and public disclosures (FDA, Silver Spring, MD, 2011).
20. D. E. Zinner et al., Health Aff. 28, 1814 (2009).
21. Association of American Medical Colleges, About the AAMC (AAMC, Washington, DC, 2012); https://www.aamc.org/about/membership/.
22. American Association of Colleges of Pharmacy, AACP Institutional Members (AACP, Alexandria, VA, 2012); www.aacp.org/about/membership/ institutionalmembership/Pages/usinstitutionalmember.aspx.
23. Association of Schools of Public Health, Member Schools (ASPH, Washington, DC, 2012); www.asph.org/document.cfm?page=200.
24. Consumer Reports National Research Center, Poll: Public wants strong medical device safety oversight (Consumer Reports, Yonkers, NY, 2012); http://consumersunion.org/news/poll-public-wants-strong-medical-device- oversight/.
25. M. A. Hamburg, Commissioner's letter to FDA staff on disclosure of financial conflicts of interest (FDA, Silver Spring MD, 2010); www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm209001.htm.